The pharmaceutical formulation according to claim 3, wherein the functional equivalent is made from a fusion between a first polypeptide that is a protein transduction domain (PTD) and a second polypeptide that is a therapeutic domain (TD).ġ8. The pharmaceutical formulation according to claim 13, wherein the polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA SEQ ID NO: 1 or the functional equivalent thereof is at a concentration of 7.0 mg/mL.ġ7. The pharmaceutical formulation according to claim 13, wherein the polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA SEQ ID NO: 1 or the functional equivalent thereof is at a concentration of 0.7 mg/mL.ġ6. The pharmaceutical formulation according to claim 13, wherein the saline is NaCl.ġ5. The pharmaceutical formulation according to claim 3 further comprising saline.ġ4. The pharmaceutical formulation according to claim 1, wherein the pharmaceutical formulation is delivered to a subject via a dry powder inhalation device (DPI).ġ3.

The pharmaceutical formulation according to claim 10, wherein the protein transduction domain (PTD) is selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 11), FAKLAARLYR (SEQ ID NO: 16), and KAFAKLAARLYR (SEQ ID NO: 17), and a second polypeptide that is a therapeutic domain (TD) of amino acid sequence KALARQLGVAA (SEQ ID NO: 2).ġ2. The pharmaceutical formulation according to claim 1, wherein the functional equivalent is made from a fusion between a first polypeptide that is a protein transduction domain (PTD) and a second polypeptide that is a therapeutic domain (TD).ġ1. The pharmaceutical formulation according to claim 7, wherein the MMI-0100 (YARAAARQARAKALARQLGVAA SEQ ID NO: 1) or the functional equivalent thereof and the trehalose are in a ratio of 92.5/7.5 respectively.ġ0. The pharmaceutical formulation according to claim 7, wherein the polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA SEQ ID NO: 1 or the functional equivalent thereof and the trehalose are in a ratio of 80/20 respectively.ĩ. The pharmaceutical formulation according to claim 2 further comprising trehalose.Ĩ.

The pharmaceutical formulation according to claim 2, wherein the pharmaceutical formulation comprises 5% w/w solids.ħ. The pharmaceutical formulation according to claim 2, wherein the pharmaceutical formulation comprises 1% w/w solids.Ħ. The pharmaceutical formulation according to claim 1, wherein the formulation is prepared by a process of spray drying.ĥ.

The pharmaceutical formulation according to claim 1, wherein the pharmaceutical formulation is an aerosolized pharmaceutical formulation.Ĥ. The pharmaceutical formulation according to claim 1, wherein the pharmaceutical formulation is a particulate pharmaceutical formulation.ģ. A pharmaceutical formulation comprising a therapeutic amount of a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA SEQ ID NO: 1 or a functional equivalent thereof, wherein the formulation is characterized by preservation of stability and bioavailability of the polypeptide.Ģ.

Labchart reader arithmetic smoothing